| Short Description : | Recombinant-SARS-COV-2 Spike RBD (K417N)-C-His protein was developed in hek293 cells using the region Arg319-Phe541. For use in research applications. |
| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Formulation: | Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity: | Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 Spike RBD (K417N) at 2 Mu g/mL (100 Mu L/well) can bind Human ACE2 with a linear range of 0.1-6.78 ng/mL. |
| Determination Method: | < 0.1 EU/Mu g of the protein by LAL method. |
| Immunogen: | Recombinant SARS-COV-2 Spike RBD (K417N) Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Arg319-Phe541 (K417N) ) of SARS-COV-2 RBD (Accession #YP_009724390.1) fused with an 6×His tag at the C-term |
| Immunogen Region: | Arg319-Phe541 |
| Immunogen Sequence: | RVQPTESIVRFPNITNLCPF GEVFNATRFASVYAWNRKRI SNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYAD SFVIRGDEVRQIAPGQTGNI ADYNYKLPDDFTGCVIAWNS NNLDSKVGGNYNYLYRLFRK SNLKPFERDISTEIYQAGST PCNGVEGFNCYFPLQSYGFQ PTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKC VNF |
